ASND — ASCENDIS PHARMA A/S

Ownership history in MACQUARIE GROUP LTD  ·  2 quarters on record

This page tracks every 13F SEC filing in which MACQUARIE GROUP LTD reported a position in ASCENDIS PHARMA A/S (ASND). Data includes quarterly share count, position size as % of portfolio, estimated market value, and end-of-quarter stock price — sourced directly from SEC EDGAR 13F filings.

Peak position
0.07% (2025 Q3)
Avg. % of fund
0.05%
First filed
2025 Q2
Last filed
2025 Q3
Quarters held
2
Quarter Action Shares Change Chg % % of Fund Mkt Value Price (EOQ)
2025 Q3 ADDED 309,539 +192,804 +165.2% 0.07% $61.5M $198.81
2025 Q2 INITIATED 116,735 — — 0.02% $20.1M $172.60
% of Fund (quarterly)    ASND price (monthly, adj. close)

Other funds also holding ASND

As of 2025 Q4 — sorted by position size

Q Global Advisors, LLC 3Y 7Y 39.86% RA CAPITAL MANAGEMENT, L.P. 3Y 7Y 22.46% Avoro Capital Advisors LLC 3Y 7Y 10.71% Resolute Capital Asset Partners LLC 3Y 9.13% Tri Locum Partners LP 3Y 7.34% WESTFIELD CAPITAL MANAGEMENT CO LP 3Y 7Y 4.61% Catalio Capital Management, LP 4.49% Spyglass Capital Management LLC 3Y 7Y 4.43% PERCEPTIVE ADVISORS LLC 3Y 7Y 4.11% PFM Health Sciences, LP 3Y 7Y 3.78%
← Back to MACQUARIE GROUP LTD Holdings